← Leaderboards
Yun Yen
City Of Hope/Beckman Research Institute
$2,967,605
Attributed
$3,168,465
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $563.6K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$3,168,465 · 5
By mechanism
R01$2,375,832 · 2
R21$401,720 · 1
R29$218,913 · 1
R03$172,000 · 1
Top collaborators
- Qiang Liu2 shared
Others in their field
Top investigators on “Ribonucleotide Reductase”
- Joanne Stubbe · Massachusetts Institute Of Technology$10,830,963
- Daniel G. Nocera · Harvard University$9,029,105
- Michael Regnier · University Of Washington$7,786,680
- Lawrence Que · University Of Minnesota Twin Cities$7,487,200
- Donna S. Shewach · University Of Michigan At Ann Arbor$6,121,517
- Jeffrey S Chamberlain · University Of Michigan At Ann Arbor$5,225,126
Research focus
Ribonucleotide ReductaseHydroxyureaDrug ResistanceProtein Protein InteractionCell LineBaseCancer CellLeadMalignant NeoplasmsCellsEnzyme Induction /RepressionAnalogGenetic Promoter ElementFigs - DietaryNeoplastic CellEnzyme ActivityEnzyme InhibitorsBench To BedsideComputersCatecholsCancer Cell LineApoptosisComputer SimulationDeoxyribonucleotides
Grant awards (14)
Drug Development of Ribonucleotide Reductase Inhibitor$334,117
R01 · FY2011 · CA · contact PI
Drug Development of Ribonucleotide Reductase Inhibitor$344,450
R01 · FY2010 · CA · contact PI
Ultrahigh sensitive, personalized monitoring of lymphoma relapse using blood spec$182,600
R21 · FY2010 · CA · contact PI
Drug Development of Ribonucleotide Reductase Inhibitor$344,450
R01 · FY2009 · CA · contact PI
Ultrahigh sensitive, personalized monitoring of lymphoma relapse using blood spec$219,120
R21 · FY2009 · CA · contact PI
Drug Development of Ribonucleotide Reductase Inhibitor$345,315
R01 · FY2008 · CA · contact PI
The Role of RR in Chemotherapeutic Drug Resistance$249,375
R01 · FY2005 · CA
Genetic Basis of Colon Adenoma Synchronous to Carcinoma.$86,000
R03 · FY2005 · CA
The Role of RR in Chemotherapeutic Drug Resistance$259,375
R01 · FY2004 · CA
Genetic Basis of Colon Adenoma Synchronous to Carcinoma.$86,000
R03 · FY2004 · CA
The Role of RR in Chemotherapeutic Drug Resistance$249,375
R01 · FY2003 · CA
The Role of RR in Chemotherapeutic Drug Resistance$249,375
R01 · FY2002 · CA
HYDROXYUREA RESISTANCE AND GENE REGULATION$111,524
R29 · FY2001 · CA
HYDROXYUREA RESISTANCE AND GENE REGULATION$107,389
R29 · FY2000 · CA